AI Usage at a Glance
Jan 1, 2023
Data AnalysisPractice documented: Boston Scientific deployed the AVVIGO+ Multi-Modality Guidance System, which includes an AI software feature called Automated Lesion Assessment that automatically identifies and measures coronary artery blockages during heart procedures. The system received FDA clearance in September 2023.
Practice DocumentedView practice →Sep 1, 2023
Data AnalysisNew evidence: Boston Scientific Gets FDA Approval for Intravascular Ultrasound
Evidence AddedView practice →Nov 13, 2023
Data AnalysisPractice documented: Boston Scientific deployed HeartLogic, an AI algorithm built into implantable cardiac defibrillators and cardiac resynchronization therapy devices that predicts worsening heart failure events weeks before they occur. The algorithm continuously analyzes sensor data from the implanted device and alerts physicians when a patient's condition is deteriorating.
Practice DocumentedView practice →Jan 1, 2024
ProductivityPractice documented: Boston Scientific offers iRCODER, a cloud-based AI tool that automates procedure charge capture and billing code assignment for hospitals performing interventional cardiology, radiology, and vascular procedures. The tool is offered to hospital customers as part of Boston Scientific's administrative solutions portfolio.
Practice DocumentedView practice →Jan 1, 2024
Data AnalysisPractice documented: Boston Scientific deployed the LUX-Dx II+ Insertable Cardiac Monitor, which uses an enhanced dual-stage algorithm to automatically detect and verify potential arrhythmias in patients before sending alerts to clinicians. The device is implanted under the skin for long-term continuous heart monitoring.
Practice DocumentedView practice →Jan 1, 2024
Data AnalysisPractice documented: Boston Scientific deployed BeatLogic, a deep-learning algorithm that automatically analyzes ECG data from cardiac monitoring devices to detect and classify 34 distinct arrhythmias. The system processes over 3 billion heartbeats daily across patients in the United States and sends critical alerts to physicians.
Practice DocumentedView practice →Jan 1, 2024
Data AnalysisNew evidence: HeartLogic Clinic Workflow - HeartLogic Implementation Program
Evidence AddedView practice →Feb 6, 2024
OtherPractice documented: Boston Scientific uses an internal AI-based omnichannel sales and marketing platform that analyzes data to deliver targeted educational messages and product information to physicians through the most relevant channel at the optimal time. Company executives publicly described this initiative at a February 2024 investor event.
Practice DocumentedView practice →Nov 1, 2024
ProductivityNew evidence: Increase revenue with intelligent charge capture at the point of care
Evidence AddedView practice →Mar 1, 2025
Data AnalysisNew evidence: Artificial Intelligence in Intravascular Imaging for Percutaneous Coronary Interventions: A New Era of Precision
Evidence AddedView practice →Apr 28, 2025
Data AnalysisNew evidence: Boston Scientific has positive ICD, Watchman FLX, AI data
Evidence AddedView practice →May 30, 2025
Data AnalysisNew evidence: Using AI to predict and prevent cardiac emergencies
Evidence AddedView practice →May 30, 2025
Data AnalysisNew evidence: Using AI to predict and prevent cardiac emergencies
Evidence AddedView practice →Aug 14, 2025
RecommendationPractice documented: Boston Scientific integrated Coveo's AI-search platform into its B2B e-commerce site to deliver personalized search results, relevance tuning, and behavior-based product recommendations for healthcare facility buyers and sales representatives. The integration has been underway for approximately four years.
Practice DocumentedView practice →Boston Scientific integrated Coveo's AI-search platform into its B2B e-commerce site to deliver personalized search results, relevance tuning, and behavior-based product recommendations for healthcare facility buyers and sales representatives. The integration has been underway for approximately four years.
Boston Scientific integrated Coveo's AI platform into its SAP Commerce Cloud stack, enabling the e-commerce site to analyze user behavior and past purchase data to surface relevant products, rank search results by predicted relevance, and recommend products to buyers. The company also introduced an 'intent box' — a unified search and chat interface — to reduce friction in product discovery. Boston Scientific has reported that the AI search improvements reduced inbound customer service calls related to product findability and order tracking.
Boston Scientific deployed the AVVIGO+ Multi-Modality Guidance System, which includes an AI software feature called Automated Lesion Assessment that automatically identifies and measures coronary artery blockages during heart procedures. The system received FDA clearance in September 2023.
The AVVIGO+ system provides intravascular ultrasound (IVUS) and fractional flow reserve (FFR) capabilities. Its AI component performs automated vessel and lumen segmentation, automatically selecting and displaying lesion length, proximal and distal reference segments, and the location of minimal lumen area. It automatically measures diameter, area, and plaque burden to assist physicians in planning stent implantation and selecting the correct device size, reducing operator variability. Boston Scientific also received CE Mark for the system, with launch in Europe planned for 2024.
Boston Scientific deployed BeatLogic, a deep-learning algorithm that automatically analyzes ECG data from cardiac monitoring devices to detect and classify 34 distinct arrhythmias. The system processes over 3 billion heartbeats daily across patients in the United States and sends critical alerts to physicians.
BeatLogic is the AI algorithm suite built into Boston Scientific's Cardiac Diagnostics cloud-based ECG analysis platform, and is also integrated across the BodyGuardian family of remote cardiac monitors. The algorithm was developed using 125,000+ patient records and 7.5+ million ECG records, applying multiple specialized deep-learning models to raw ECG input to produce classified arrhythmia reports and urgent notifications. A clinical study found that AI-guided rhythm adjudication using BeatLogic was near-identical in accuracy to a consensus of three expert electrophysiologists.
Boston Scientific deployed the AVVIGO+ Multi-Modality Guidance System, which includes an AI software feature called Automated Lesion Assessment that automatically identifies and measures coronary artery blockages during heart procedures. The system received FDA clearance in September 2023.
Boston Scientific deployed BeatLogic, a deep-learning algorithm that automatically analyzes ECG data from cardiac monitoring devices to detect and classify 34 distinct arrhythmias. The system processes over 3 billion heartbeats daily across patients in the United States and sends critical alerts to physicians.
Boston Scientific deployed the LUX-Dx II+ Insertable Cardiac Monitor, which uses an enhanced dual-stage algorithm to automatically detect and verify potential arrhythmias in patients before sending alerts to clinicians. The device is implanted under the skin for long-term continuous heart monitoring.
Boston Scientific deployed HeartLogic, an AI algorithm built into implantable cardiac defibrillators and cardiac resynchronization therapy devices that predicts worsening heart failure events weeks before they occur. The algorithm continuously analyzes sensor data from the implanted device and alerts physicians when a patient's condition is deteriorating.
Have evidence about Boston Scientific's AI practices? Submit a report.
Submit a report →AI Trace is free and nonprofit. Support our work